Urinary Urgency Incontinence
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Neuspera MedicalCA - San Jose
2 programsNeuspera Implantable Sacral Nerve Stimulation SystemN/A1 trial
Neuspera Implantable Sacral Neuromodulation SystemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Neuspera MedicalNeuspera Implantable Sacral Neuromodulation System
Neuspera MedicalNeuspera Implantable Sacral Nerve Stimulation System
Clinical Trials (2)
Total enrollment: 447 patients across 2 trials
Post-Approval Study of the Neuspera Sacral Neuromodulation System
Start: Sep 2025Est. completion: Dec 2029116 patients
N/ARecruiting
Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI)
Start: Dec 2019Est. completion: Dec 2026331 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 447 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.